New DNA HIV vaccine shows promise in early safety trial

NCT ID NCT05828095

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested a new DNA-based HIV vaccine (INO-6160) alone or with a protein booster in 20 healthy adults without HIV. The main goal was to see if the vaccine is safe and whether it triggers antibodies and T-cells against HIV. The study is complete, and results will help decide if larger trials should move forward.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
DNA vaccine (INO-6160) and protein booster (VRC HIV Env Trimer 4571 with adjuvant)
What this could lead to
If successful, this could point toward a safe and effective HIV vaccine that triggers strong immune responses.
What could go wrong
This is a very early Phase 1 trial with only 20 participants. It primarily tests safety, not whether the vaccine prevents HIV. Many early vaccine candidates fail to show enough immune response to move forward.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • New York Blood Center CRS

    New York, New York, 10065, United States

  • Penn Prevention CRS

    Philadelphia, Pennsylvania, 19104, United States

  • Vanderbuilt Vaccine (VV) CRS

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.